Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
RESEARCH TOOLSreports
AN2 Therapeutics, Inc. (ANTX) Stock Price & Analysis
59 Followers
ANTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.31 - $22.22
Previous Close$2.37
Volume178.94K
Average Volume (3M)478.99K
Market Cap
$70.56M
Enterprise Value-$53.25M
Total Cash (Recent Filing)$123.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.8
Beta1.61
Next Earnings
May 08, 2024EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding29,770,375
10 Day Avg. Volume148,411
30 Day Avg. Volume478,988
Standard Deviation0.38
R-Squared0.00121
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.19
Forecast
1Y Price Target
$6.00Price Target Upside163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
AN2 Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst initiates coverage of AN2 Therapeutics with a Market Outperform rating and a $30 price target.
Clinical Trial ProgressEnrollment of more severe patients could still provide an opportunity for the drug arm to separate from placebo.
Drug Approval PotentialEpetraborole may become the first FDA-approved oral option for refractory MAC NTM lung disease.
Bears Say
Approval ProbabilityLowered probability of approval for epetraborole in refractory MAC NTM to 25%, from 65%.
Clinical Trial ConcernsVoluntary pausing of enrollment in Phase 3 trial for epetraborole due to potentially low efficacy as observed by the data safety monitoring board.
Drug EfficacyEpetraborole efficacy called into question; downgrading to Market Perform on AN2 Therapeutics.
---
Ownership Overview
42.91% Insiders
5.49% Mutual Funds
3.69% Other Institutional Investors
47.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $2.31 and its highest was $22.22 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
Currently, no data Available
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is May 08, 2024 which is in 12 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on Mar 28, 2024. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.736 by $0.166.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -$0.62.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 29,770,374 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.736. Following the earnings report the stock price went up 15.692%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Among the largest hedge funds holding AN2 Therapeutics, Inc.’s share is RA Capital Management. It holds AN2 Therapeutics, Inc.’s shares valued at 114M.
---
AN2 Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (163.16% Upside)
$6.00 (163.16% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.79%
12-Months-Change
Fundamentals
Return on Equity
-58.83%
Trailing 12-Months
Asset Growth
35.28%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
---
ANTX Stock 12 Months Forecast
Average Price Target
$6.00
▲(163.16% Upside)
Technical Analysis
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-51.23%
reiterated a buy rating 24 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.23% per trade.
---